A photoredox catalytic strategy is reported for the direct trifluoromethylation of unactivated arenes and heteroarenes. This method uses commercial photocatalysts and a household light bulb, offering a mild and operationally simple approach. The strategy enables the direct installation of the trifluoromethyl group (CF3) into various aromatic and heteroaromatic systems, including biologically active molecules. The CF3 group enhances drug efficacy by promoting electrostatic interactions with targets, improving membrane permeability, and increasing resistance to oxidative metabolism. Traditional methods for CF3 incorporation often require pre-functionalized substrates and metal-catalyzed cross-coupling reactions, which are limited in generality. The photoredox approach circumvents this by directly installing CF3 at metabolically susceptible positions, avoiding the need for pre-functionalization. The mechanism involves the generation of a CF3 radical through the reduction of triflyl chloride (TfCl) by a photocatalyst, followed by radical addition to aromatic systems. The process is efficient and applicable to a wide range of substrates, including five- and six-membered heteroarenes, as well as arenes. The method is also applicable to late-stage drug development, enabling the direct trifluoromethylation of pharmaceutical agents. The strategy is supported by experimental data, including emission quenching experiments and cyclic voltammetry. The use of a household light bulb and commercial photocatalysts makes this method accessible and cost-effective. The approach offers a complementary method to traditional cross-coupling strategies, providing a new and efficient way to introduce metabolism-blocking fluoroalkyl groups in drug development.A photoredox catalytic strategy is reported for the direct trifluoromethylation of unactivated arenes and heteroarenes. This method uses commercial photocatalysts and a household light bulb, offering a mild and operationally simple approach. The strategy enables the direct installation of the trifluoromethyl group (CF3) into various aromatic and heteroaromatic systems, including biologically active molecules. The CF3 group enhances drug efficacy by promoting electrostatic interactions with targets, improving membrane permeability, and increasing resistance to oxidative metabolism. Traditional methods for CF3 incorporation often require pre-functionalized substrates and metal-catalyzed cross-coupling reactions, which are limited in generality. The photoredox approach circumvents this by directly installing CF3 at metabolically susceptible positions, avoiding the need for pre-functionalization. The mechanism involves the generation of a CF3 radical through the reduction of triflyl chloride (TfCl) by a photocatalyst, followed by radical addition to aromatic systems. The process is efficient and applicable to a wide range of substrates, including five- and six-membered heteroarenes, as well as arenes. The method is also applicable to late-stage drug development, enabling the direct trifluoromethylation of pharmaceutical agents. The strategy is supported by experimental data, including emission quenching experiments and cyclic voltammetry. The use of a household light bulb and commercial photocatalysts makes this method accessible and cost-effective. The approach offers a complementary method to traditional cross-coupling strategies, providing a new and efficient way to introduce metabolism-blocking fluoroalkyl groups in drug development.